NCT06660368 2026-04-01
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05330377 2023-04-25
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
University of Kentucky
Phase 1 Withdrawn
NCT02298166 2021-10-06
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
Phase 3 Terminated
NCT01483690 2020-10-27
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT02631252 2018-02-23
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
University of Pittsburgh
Phase 1 Terminated
NCT01681537 2016-03-17
Lenalidomide Plus Chemotherapy for AML
Massachusetts General Hospital
Phase 1 Completed
NCT00660036 2016-01-15
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
University of Pittsburgh
Phase 1 Terminated
NCT01279096 2014-12-09
Vandevol
University Hospital, Lille
Phase 1 Completed
NCT00047021 2010-06-11
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
Case Comprehensive Cancer Center
Phase 2 Completed